1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
CONMED Corporation

CONMED Corporation

CNMD
CONMED CorporationUS flagNew York Stock Exchange
33.06
USD
-0.79
- -
995.41MMarket Cap
CONMED Corporation
CNMD
(New York Stock Exchange)

Recent

price

33.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
24.86
25.67
27.11
27.51
27.01
26.01
27.46
28.5
30.57
33.72
30.18
34.66
34.8
40.59
42.37
44.29
44.4
Revenue per Share
1.06
0.03
1.43
1.3
1.17
1.1
0.53
1.99
1.45
1.01
0.33
2.14
-2.68
2.1
4.29
1.52
1.78
Basic EPS, GAAP
0.82
3.02
2.6
2.25
1.82
1.3
0.9
1.89
2.07
2.65
1.8
3.32
0.39
3.47
4.99
4.86
4.01
Free Cash Flow per Basic Share
- -
- -
0.45
0.6
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.6
Dividend per Share
12.34
12.56
13.36
14.29
14.83
15
14.65
15.76
16.54
16.63
16.02
17.04
13.75
14.77
18.17
18.98
19.53
Book Value per Share
3.53
5.05
0.86
1.39
0.31
0.59
-8.51
-6.64
-5.38
-15.55
-14.38
-10.4
-25.02
-20.29
-14.92
-11.47
-11.76
Tangible Book Value per Share
29
28
28
28
27
28
28
28
28
28
29
29
30
31
31
31
31
Basic Weighted Avg Shares
714
725
767
763
740
719
764
796
860
955
862
1,011
1,045
1,245
1,307
1,375
1,371
Sales/Revenue/Turnover
8
9.46
8.86
7.41
7.13
7.12
4.93
5.89
8.29
8.28
5.33
10.86
6.7
9.69
15.33
7.46
8.18
Operating Margin (%)
38
39
47
48
46
44
55
58
61
72
73
71
70
72
72
74
75
Depreciation Expense
30
1
40
36
32
30
15
55
41
29
10
63
-81
64
132
47
55
Net Income, GAAP
33.53
- -
31.94
29.02
31.03
32.44
24.31
- -
19.35
8.34
- -
14.45
- -
20.25
18.77
33.83
32.95
Effective Tax Rate (%)
4.25
0.1
5.28
4.71
4.35
4.24
1.92
6.97
4.75
3
1.1
6.19
-7.71
5.18
10.13
3.42
4
Profit Margin (%)
170
226
224
261
265
240
217
207
213
209
226
263
285
305
362
358
378
Working Capital
85
89
161
214
240
269
488
472
439
772
735
672
985
973
905
834
860
LT Debt
587
573
607
606
581
585
581
631
662
710
709
785
746
834
963
1,033
1,018
Total Equity
4.92
- -
6.2
5.04
4.42
4.11
2.95
- -
5.15
5.54
- -
6.42
- -
5.35
8.88
3.65
4.01
Return on Invested Capital (%)
7.15
- -
8.55
6.93
5.78
5.19
3.3
- -
6.22
6.2
- -
7.76
- -
6.65
11.25
4.68
5.13
Return on Capital (%)
8.93
0.21
11.05
9.28
8.02
7.43
3.57
13.09
9.02
6.11
2.05
13.1
-17.71
14.89
26.13
8.19
9.43
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
853
834
860
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
30
Market Capitalization
1,456
1,257
1,091

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
662
673
671
Cash, Cash Equivalents & STI
39
41
35
Accounts Receivable, Net
225
248
229
Inventories
364
356
366
Total Current Liabilities
315
315
293
Payables & Accruals
107
94
105
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.02%
8.06%
7.31%
Free Cash Flow
94.87%
172.19%
-1.95%
Net Income, GAAP
29.27%
37.86%
-64.47%
Sales/Revenue/Turnover
6.97%
9.97%
5.18%
Total Cash Common Dividend
1.14%
1.64%
0.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
312
332
317
346
1,307
2025
321
342
338
373
1,375
2026
317
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.64
0.97
1.59
1.09
4.29
2025
0.19
0.69
0.09
0.54
1.52
2026
0.45
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.2
0.2
0.2
0.8
2025
0.2
0.2
0.2
0.2
0.8
2026
- -
- -
- -
- -
- -
Similar Companies
Creo Medical Limited (CREO.L)
HeartSciences Inc. (HSCS)
Edwards Lifesciences Corporation (EW)
Guided Therapeutics, Inc. (GTHP)
Inspiration Healthcare Group plc (IHC.L)
InnoCare Optoelectronics Corporation (6861.TW)
Business
CONMED Corporation (NYSE: CNMD) develops, manufactures, and markets surgical devices and supplies for use in minimally invasive procedures and orthopedics worldwide. The company offers a broad portfolio of products including powered instruments such as the Buffalo Filter and HiClear Oscillating Saw; orthopedic implants and biologics under brands like BioBrace and CrossFix; endoscopy devices including the DuraClip and OneSnip; general surgery instruments like the Repose Retractor System; and patient positioners such as the Plastech Gel products. CONMED operates through two primary segments—Orthopedic Surgery and General Surgery—serving hospitals, ambulatory surgery centers, and outpatient clinics primarily in the United States, Europe, and Asia-Pacific. Founded in 1970 and headquartered in Largo, Florida, the company maintains manufacturing facilities in the U.S., Mexico, and Poland. In recent developments, CONMED completed the acquisition of In2Bones Global, Inc. in March 2024, expanding its upper extremity orthopedic portfolio with innovative implants and instrumentation; launched the next-generation AirSeal iGS system in 2024 to enhance laparoscopic procedures; and reported strong revenue growth in its orthopedic segment during 2025, driven by strategic investments in sports medicine and trauma solutions.[web:previous]

Company News

APIChat

  • zacks.com

    Here's Why You Should Retain CONMED Stock in Your Portfolio Now

  • zacks.com

    Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report?

  • zacks.com

    Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?

  • gurufocus.com

    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

  • businesswire.com

    CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

  • zacks.com

    Is the Options Market Predicting a Spike in CONMED Stock?

  • zacks.com

    CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up

  • seekingalpha.com

    CONMED Corporation (CNMD) Q1 2026 Earnings Call Transcript

  • zacks.com

    Compared to Estimates, Conmed (CNMD) Q1 Earnings: A Look at Key Metrics

  • zacks.com

    Conmed (CNMD) Q1 Earnings and Revenues Beat Estimates

  • businesswire.com

    CONMED Corporation Announces First Quarter 2026 Financial Results

  • gurufocus.com

    A Look at Conmed Corp (CNMD) After 3.3% Gain -- GF Value $78.09 vs Price $39.73

  • zacks.com

    Here's Why You Should Retain CONMED Stock in Your Portfolio Now

  • businesswire.com

    CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

  • defenseworld.net

    CONMED Corporation (NYSE:CNMD) Given Consensus Recommendation of “Reduce” by Analysts

  • zacks.com

    Here's Why You Should Retain CONMED Stock in Your Portfolio Now

  • zacks.com

    Conmed (CNMD) Up 22.9% Since Last Earnings Report: Can It Continue?

  • zacks.com

    Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

  • defenseworld.net

    CONMED Corporation (NYSE:CNMD) Receives Consensus Recommendation of “Reduce” from Analysts

  • defenseworld.net

    CONMED Q4 Earnings Call Highlights